{"product_id":"olieni-olaparib-50mg-2","title":"Olieni 50 (Olaparib)","description":" \r\n\u003cdiv class=\"woocommerce-product-details__short-description\"\u003e\r\n\r\n\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nOlieni is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\r\n\r\nOlieni was approved by the FDA due to its objective response rate and response duration. Further of this indication\r\n\r\nApproval depends on the results of clinical benefit in confirmatory clinical trials.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\r\n \t\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\r\n \t\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications: None.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\r\n \t\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\r\n \t\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\r\n \t\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eStorage method\u003c\/strong\u003e\r\n\r\nStore between 20-25°C.\r\n\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947478059,"sku":"RL1420230901255","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655264792-96bfa0933e18e60.jpg?v=1787022095","url":"https:\/\/xomeds.com\/products\/olieni-olaparib-50mg-2","provider":"XOMEDS","version":"1.0","type":"link"}